Antibody‐Dependent Cellular Cytotoxicity of iPS Cell‐Derived Natural Killer T Cells by Anti‐ GD2 mAb for Neuroblastoma
Rattachement africain : jp. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
While antibody-dependent cellular cytotoxicity (ADCC) by anti-disialoganglioside GD2 monoclonal antibody (mAb) has succeeded in increasing the survival rate of high-risk patients with neuroblastoma, approximately 40%-50% of patients die from the disease. Recently, we developed induced pluripotent stem cell-derived natural killer T (iPS-NKT) cells, which exhibit NK-like cytotoxicity. However, whether iPS-NKT cells can induce ADCC function is unclear. Here, we investigated the ADCC of iPS-NKT cells and the efficacy of the combination treatment of anti-GD2 mAb and iPS-NKT cells against neuroblastoma. Anti-GD2 mAb enhanced the cytotoxicity and secretion of cytokines and cytotoxic granules of iPS-NKT cells, which expressed CD16 to GD2-expressing neuroblastoma cell lines. We also examined which Fcγ receptors contribute to ADCC of iPS-NKT cells. CD16 stimulation against iPS-NKT cells caused cytotoxicity and secretion of interferon-gamma, tumor necrosis factor, and granzyme B. In contrast, CD32 and CD64 stimulation did not. In vivo, the intratumor administration of anti-GD2 mAb and iPS-NKT cells significantly inhibited tumor growth compared with the other treatment groups: no treatment, anti-GD2 mAb alone, and iPS-NKT cells alone. In conclusion, iPS-NKT cells exhibit CD16-mediated ADCC, and the addition of iPS-NKT cells to anti-GD2 mAb therapy may be a potential approach for immunotherapy against neuroblastoma.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé, mais le titre doit être comparé manuellement.
- Titre Crossref
- Antibody‐Dependent Cellular Cytotoxicity of <scp>iPS</scp> Cell‐Derived Natural Killer T Cells by Anti‐<scp>GD2 mAb</scp> for Neuroblastoma
- Date Crossref
- 06/02/2025
- Éditeur
- Wiley
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Chiba University Department of Medical Immunology pays non établi dans la noticeUniversité ou école supérieure
-
RIKEN Center for Integrative Medical Sciences pays non établi dans la noticeStructure de recherche
-
Graduate School of Medicine Department of Medical Immunology pays non établi dans la noticeUniversité ou école supérieure
-
Laboratory for Developmental Genetics pays non établi dans la noticeStructure de recherche
Department of Medical Immunology — Chiba University, RIKEN Center for Integrative Medical Sciences et Department of Medical Immunology — Graduate School of Medicine, avec 1 autre affiliation.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.